CENTESSA PHARMACEUTICALS PLC ADS news, videos and press releases
For more news please use our advanced search feature.
CENTESSA PHARMACEUTICALS PLC ADS - More news...
CENTESSA PHARMACEUTICALS PLC ADS - More news...
- Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
- Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
- Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
- Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
- Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
- Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
- Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
- Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
- Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
- Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
- Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
